LV305, a dendritic cell-targeting integration-deficient ZVex TM -based lentiviral vector encoding NY-ESO-1, induces potent anti-tumor immune response-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

LV305, a dendritic cell-targeting integration-deficient ZVex TM -based lentiviral vector encoding NY-ESO-1, induces potent anti-tumor immune response

Published:2016 Issue: Volume:3 Page:16010
ISSN:2372-7705
Container-title:Molecular Therapy - Oncolytics
language:en
Short-container-title:Molecular Therapy - Oncolytics

Author:

Albershardt Tina Chang,Campbell David James,Parsons Andrea Jean,Slough Megan Merrill,ter Meulen Jan,Berglund Peter

Publisher

Elsevier BV

Subject

Pharmacology (medical),Cancer Research,Oncology,Molecular Medicine

Reference43 articles.

1. Induction of effective therapeutic antitumor immunity by direct in vivo administration of lentiviral vectors;Dullaers;Gene Ther,2006

2. In vivo administration of a lentiviral vaccine targets DCs and induces efficient CD8(+) T cell responses;Esslinger;J Clin Invest,2003

3. Skin-derived dendritic cells induce potent CD8(+) T cell immunity in recombinant lentivector-mediated genetic immunization;He;Immunity,2006

4. Immunization with lentiviral vector-transduced dendritic cells induces strong and long-lasting T cell responses and therapeutic immunity;He;J Immunol,2005

5. Engineered lentivector targeting of dendritic cells for in vivo immunization;Yang;Nat Biotechnol,2008

Cited by 32 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. NY‐ESO‐1 antigen: A promising frontier in cancer immunotherapy;Clinical and Translational Medicine;2024-09

2. Fusion of NY-ESO-1 epitope with heat shock protein 70 enhances its induced immune responses and antitumor activity against glioma in vitro;Translational Cancer Research;2024-01

3. Tumor Vaccines: Unleashing the Power of the Immune System to Fight Cancer;Pharmaceuticals;2023-09-29

4. Lentiviral Vectors as a Vaccine Platform against Infectious Diseases;Pharmaceutics;2023-03-05

5. Current Advances in PD-1/PD-L1 Blockade in Recurrent Epithelial Ovarian Cancer;Frontiers in Immunology;2022-06-27

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3